博瑞醫藥(688166.SH):阿加曲班注射液、磷酸奧司他韋幹混懸劑擬中標第八批全國藥品集採
格隆匯3月30日丨博瑞醫藥(688166.SH)公佈,公司全資子公司博瑞製藥(蘇州)有限公司(簡稱“博瑞製藥”)參加了聯合採購辦公室組織的第八批全國藥品集中採購的投標工作。經聯合採購辦公室開標、評標後,博瑞製藥產品阿加曲班注射液、磷酸奧司他韋幹混懸劑擬中標該次集中採購。
博瑞製藥此次擬中標產品阿加曲班注射液於2022年3月獲得國家藥品監督管理局核准簽發的藥品註冊證書。公司阿加曲班注射液2022年1-9月銷售收入為137.26萬元,佔2022年1-9月公司營業收入的0.18%。
磷酸奧司他韋幹混懸劑於2022年6月獲得國家藥品監督管理局核准簽發的藥品註冊證書。公司磷酸奧司他韋幹混懸劑2022年1-9月銷售收入為74.86萬元,佔2022年1-9月公司營業收入的0.10%。
該次藥品集中採購是國家組織的第八批國家藥品集中採購,在執行上要求全國醫療機構優先使用集中採購中選品種,並確保完成約定採購量。該次博瑞製藥擬中選價格與原銷售價格相比有一定程度下降。
該次擬中選的品種若確定中選、簽訂購銷合同並實施後,將有利於上述產品快速打開國內銷售市場,提高市場佔有率,促進公司製劑業務的進一步發展,提升公司品牌影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.